Celgene and AstraZeneca/MedImmune are investigating the potential of PD-L1 inhibitors in hematologic malignancies.
Use the arrows on the slider below to navigate to a trial icon, then scroll down to view detailed information about the specific trial.
LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA
A phase 1/2 open-label, multicenter study to assess the safety and tolerability of durvalumab (anti–PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic lymphocytic leukemia.
A phase 2 open-label, multicenter study to evaluate the safety and clinical activity of durvalumab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or with lenalidomide + R-CHOP in subjects with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL).
MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA
A randomized, multicenter, open-label phase 2 study evaluating the efficacy and safety of azacitidine subcutaneous in combination with durvalumab (MEDI4736) in previously untreated subjects with higher-risk myelodysplastic syndromes or in elderly patients (≥ 65 years) acute myeloid leukaemia subjects not eligible for hematopoietic stem cell transplantation.
A phase 2 international, multicenter, randomized, open-label, parallel-group study to evaluate the efficacy and safety of CC-486 alone and in combination with durvalumab (MEDI4736) in patients with MDS who fail to achieve an objective response to treatment with azacitidine for injection or decitabine.
To view To return to www.researchoncology.com